首页> 美国卫生研究院文献>Frontiers in Microbiology >The ins and outs of RND efflux pumps in Escherichia coli
【2h】

The ins and outs of RND efflux pumps in Escherichia coli

机译:RND外排泵在大肠杆菌中的来龙去脉

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Infectious diseases remain one of the principal causes of morbidity and mortality in the world. Relevant authorities including the WHO and CDC have expressed serious concern regarding the continued increase in the development of multidrug resistance among bacteria. They have also reaffirmed the urgent need for investment in the discovery and development of new antibiotics and therapeutic approaches to treat multidrug resistant (MDR) bacteria. The extensive use of antimicrobial compounds in diverse environments, including farming and healthcare, has been identified as one of the main causes for the emergence of MDR bacteria. Induced selective pressure has led bacteria to develop new strategies of defense against these chemicals. Bacteria can accomplish this by several mechanisms, including enzymatic inactivation of the target compound; decreased cell permeability; target protection and/or overproduction; altered target site/enzyme and increased efflux due to over-expression of efflux pumps. Efflux pumps can be specific for a single substrate or can confer resistance to multiple antimicrobials by facilitating the extrusion of a broad range of compounds including antibiotics, heavy metals, biocides and others, from the bacterial cell. To overcome antimicrobial resistance caused by active efflux, efforts are required to better understand the fundamentals of drug efflux mechanisms. There is also a need to elucidate how these mechanisms are regulated and how they respond upon exposure to antimicrobials. Understanding these will allow the development of combined therapies using efflux inhibitors together with antibiotics to act on Gram-negative bacteria, such as the emerging globally disseminated MDR pathogen Escherichia coli ST131 (O25:H4). This review will summarize the current knowledge on resistance-nodulation-cell division efflux mechanisms in E. coli, a bacteria responsible for community and hospital-acquired infections, as well as foodborne outbreaks worldwide.
机译:传染病仍然是世界上发病率和死亡率的主要原因之一。包括WHO和CDC在内的有关当局对细菌之间多重耐药性的发展持续增加表示严重关切。他们还重申迫切需要投资来发现和开发新的抗生素以及治疗耐多药(MDR)细菌的治疗方法。抗菌化合物在包括农业和医疗保健在内的各种环境中的广泛使用已被确定为导致MDR细菌出现的主要原因之一。诱导的选择性压力已导致细菌开发出防御这些化学物质的新策略。细菌可以通过多种机制来实现这一目标,包括目标化合物的酶促失活;细胞通透性降低;目标保护和/或生产过剩;由于外排泵的过表达,改变了靶位点/酶并增加了外排。外排泵可以专用于单个基质,也可以通过促进从细菌细胞中挤出多种化合物(包括抗生素,重金属,杀生物剂等)来赋予对多种抗菌剂的抗性。为了克服由主动外排引起的抗药性,需要努力以更好地了解药物外排机制的基本原理。还需要阐明如何调节这些机制以及它们在暴露于抗菌剂后如何反应。了解这些将允许开发使用外排抑制剂和抗生素共同作用于革兰氏阴性细菌(例如新兴的全球传播的MDR病原体大肠杆菌ST131(O25:H4))的联合疗法。这篇综述将总结有关大肠杆菌中耐药性结节性细胞分裂外排机制的最新知识,大肠杆菌是导致社区和医院获得性感染以及全球食源性疾病暴发的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号